US Legal and Regulatory Update
Journal of Generic Medicines (2007) 4, 287–292. doi:10.1057/palgrave.jgm.4950080; published online 22 May 2007
Indirect patent infringement in the US: Points to consider for generic and API manufacturers
Compiled and written by Greenblum & Bernstein plc
—a US intellectual property law firm which provides a full range of services in IP-related matters for biotech and pharmaceutical companies, including:
Drafting of patent applications
Patent prosecution
Patent and trademark litigation
Patent infringement and validity opinions
Patent interference litigation
Abbreviated new drug applications (ANDAs)
New drug strategies
Market entry strategies
Joint venture strategies
Licensing
This section is intended to be a synopsis of recent developments and is not intended to be exhaustive. If any issue in this section is to be relied upon, specific advice should be sought. Please contact:
Paul Braier
Greenblum & Bernstein plc
1950 Roland Clarke Place
Reston, VA 20191
USA
Tel: +1 703 716 1191
Fax: +1 703 716 1180
The firm is one of the founding members of the Association of Patent Law Firms.
Paul A Braier1 and Azza M Jayaprakash2
1is a partner at Greenblum & Bernstein, P.L.C.
2is an associate at Greenblum & Bernstein, P.L.C.
